Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Increase in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 221,200 shares, a growth of 322.1% from the March 15th total of 52,400 shares. Based on an average daily volume of 398,900 shares, the short-interest ratio is presently 0.6 days. Approximately 1.9% of the shares of the company are sold short.

Indaptus Therapeutics Price Performance

Shares of Indaptus Therapeutics stock traded down $0.02 on Wednesday, hitting $0.48. The company had a trading volume of 18,589 shares, compared to its average volume of 141,672. Indaptus Therapeutics has a 52 week low of $0.43 and a 52 week high of $3.10. The business has a 50-day simple moving average of $0.70 and a 200-day simple moving average of $0.94. The company has a market cap of $6.97 million, a PE ratio of -0.28 and a beta of 1.62.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. On average, equities research analysts predict that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.